News
ARGX
887.18
-0.17%
-1.47
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
Benzinga · 1d ago
Jefferies Keeps Their Buy Rating on Argenx Se (ARGX)
TipRanks · 2d ago
argenx Price Target Maintained With a $940.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on argenx, Maintains $940 Price Target
Benzinga · 2d ago
Argenx Buy Rating Reiterated as Analyst Sees Undervalued Vyvgart Myositis Opportunity; $940 Price Target Maintained
TipRanks · 2d ago
Analysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Ionis Pharmaceuticals (IONS)
TipRanks · 2d ago
Wedbush Sticks to Their Buy Rating for Argenx Se (ARGX)
TipRanks · 3d ago
argenx Is Maintained at Overweight by Morgan Stanley
Dow Jones · 3d ago
Okta To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Compugen (CGEN), Beta Bionics, Inc. (BBNX) and Argenx Se (ARGX)
TipRanks · 3d ago
Morgan Stanley Maintains Overweight on argenx, Raises Price Target to $1180
Benzinga · 3d ago
Argenx price target raised to $1,180 from $1,170 at Morgan Stanley
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: AdaptHealth (AHCO), Argenx Se (ARGX) and Nuvectis Pharma (NVCT)
TipRanks · 3d ago
TD Cowen Reaffirms Their Buy Rating on Argenx Se (ARGX)
TipRanks · 3d ago
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Verastem (VSTM)
TipRanks · 3d ago
Analysts’ Top Healthcare Picks: Dyne Therapeutics (DYN), Argenx Se (ARGX)
TipRanks · 3d ago
Barclays Reaffirms Their Buy Rating on arGEN X (0QW0)
TipRanks · 3d ago
Biotech breakout: iShares Biotechnology ETF hits all-time high
Seeking Alpha · 3d ago
Argenx Showcases Autoimmune Myositis R&D in June 23 FcRn Webinar
TipRanks · 4d ago
argenx to Host Autoimmune Myositis R&D Webinar
Barchart · 4d ago
More
Webull provides a variety of real-time ARGX stock news. You can receive the latest news about Argenx Se through multiple platforms. This information may help you make smarter investment decisions.
About ARGX
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.